Alzheimer’s Research UK has launched the Global Clinical Trials Fund (GCTF) to help finance trials which aim to translate discoveries in the lab into clinical treatments for the 830,000 people living with dementia in the UK. The GCTF aims to raise £20 million over five years for clinical trials, whether for exploring new experimental drugs and or in testing the potential for “re-purposing” existing drugs originally developed for other conditions to help people with dementia. The GCTF will also contribute to funding non-drug “intervention” trials, to determine whether specific interventions might improve certain aspects of dementia, such as symptoms or the course of the disease.
This web page briefly explains the course of clinical trials, from Phase 1 to Phase III, with an infographic. The GCTF will support Phase I and Phase II trials primarily. The pharmaceutical industry is more likely to fund Phase III trials and beyond.
O’Brien, E. (2014). The Global Clinical Trials Fund: drugs and dummies. London [Online]: Alzheimer’s Research UK, December 2014.